Chen Yang#, Dongliang Mao#, Qianyun He, Chen Wang and Mei Wang*
Department of Oncology, Shanghai Jiao Tong University, China
#These authors contributed equally to this work
Gastric cancer remains a major global health burden with high recurrence and mortality rates, especially in countries in East Asia. Studies have shown that gastric cancer presenting with lymphedema has poor survival. Furthermore, no standard treatment has been accepted for metastatic gastric cancer with lymphedema. In this report, we present a case of advanced gastric cancer with persistent lymphedema after gastrectomy. ERBB3 V104M mutation was identified by next-generation sequencing. The patient did not have a good response to nivolumab-based treatment with pyrotinib plus chemotherapy. Advanced gastric cancer with refractory lymphedema remains a challenge with immunotherapy based treatment.
Gastric cancer; Lymphedema; Nivolumab; ERBB3; Pyrotinib
Yang C, Mao D, He Q, Wang C, Wang M. Persistent Lymphedema in a Patient with Advanced Gastric Cancer with ERBB3 Mutation. Clin Oncol. 2022;7:1930..